S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: Clinical value of expression analysis in 98 pancreatic juice samples

Kenoki Ohuchida, Kazuhiro Mizumoto, Jun Yu, Hiroshi Yamaguchi, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, Masao Tanaka

Research output: Contribution to journalArticle

Abstract

There are few reports describing the diagnostic significance of S100A6 expression in clinical samples obtained from patients with pancreatic disease. In the present study, we measured S100A6 expression in pancreatic tissues and juice to evaluate its involvement in pancreatic carcinogenesis. We did quantitative real-time reverse transcription-PCR to measure mRNA expression in microdissected cells and pancreatic juice samples. Microdissected invasive ductal carcinoma and intraductal papillary mucinous neoplasm (IPMN) cells expressed significantly higher levels of S100A6 than did microdissected pancreatitis-affected epithelial and normal cells (all comparison; P <0.008). Median levels of S100A6 in invasive ductal carcinoma were higher than those in IPMN, and those in pancreatitis-affected epithelial cells tended to be higher than those in normal cells, although these differences were not statistically significant. In analyses of pancreatic juice, IPMN and pancreatic cancer samples expressed significantly higher levels of S100A6 than did chronic pancreatitis samples (both; P <0.017), but levels in pancreatic cancer and IPMN samples did not differ form each other. Receiver operating characteristic (ROC) curve analysis revealed that measurement of S100A6 was useful for discriminating cancer (area under the ROC curve, 0.864) or IPMN (area under the ROC curve, 0.749) from chronic pancreatitis. The present data suggest that expression of S100A6 is increased in a stepwise manner during pancreatic carcinogenesis and may be a biomarker for evaluating malignant potential. Measurement of S100A6 in pancreatic juice may be useful to detect early pancreatic cancer or identify individuals with high-risk lesions that may progress to pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)649-654
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Pancreatic Juice
Carcinogenesis
Pancreatic Neoplasms
ROC Curve
Neoplasms
Ductal Carcinoma
Chronic Pancreatitis
Pancreatitis
Epithelial Cells
Pancreatic Diseases
Reverse Transcription
Biomarkers
Polymerase Chain Reaction
Messenger RNA

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

S100A6 is increased in a stepwise manner during pancreatic carcinogenesis : Clinical value of expression analysis in 98 pancreatic juice samples. / Ohuchida, Kenoki; Mizumoto, Kazuhiro; Yu, Jun; Yamaguchi, Hiroshi; Konomi, Hiroyuki; Nagai, Eishi; Yamaguchi, Koji; Tsuneyoshi, Masazumi; Tanaka, Masao.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 4, 04.2007, p. 649-654.

Research output: Contribution to journalArticle

Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Yu, Jun ; Yamaguchi, Hiroshi ; Konomi, Hiroyuki ; Nagai, Eishi ; Yamaguchi, Koji ; Tsuneyoshi, Masazumi ; Tanaka, Masao. / S100A6 is increased in a stepwise manner during pancreatic carcinogenesis : Clinical value of expression analysis in 98 pancreatic juice samples. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 4. pp. 649-654.
@article{a36ab417a77747a59f538969a1114f66,
title = "S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: Clinical value of expression analysis in 98 pancreatic juice samples",
abstract = "There are few reports describing the diagnostic significance of S100A6 expression in clinical samples obtained from patients with pancreatic disease. In the present study, we measured S100A6 expression in pancreatic tissues and juice to evaluate its involvement in pancreatic carcinogenesis. We did quantitative real-time reverse transcription-PCR to measure mRNA expression in microdissected cells and pancreatic juice samples. Microdissected invasive ductal carcinoma and intraductal papillary mucinous neoplasm (IPMN) cells expressed significantly higher levels of S100A6 than did microdissected pancreatitis-affected epithelial and normal cells (all comparison; P <0.008). Median levels of S100A6 in invasive ductal carcinoma were higher than those in IPMN, and those in pancreatitis-affected epithelial cells tended to be higher than those in normal cells, although these differences were not statistically significant. In analyses of pancreatic juice, IPMN and pancreatic cancer samples expressed significantly higher levels of S100A6 than did chronic pancreatitis samples (both; P <0.017), but levels in pancreatic cancer and IPMN samples did not differ form each other. Receiver operating characteristic (ROC) curve analysis revealed that measurement of S100A6 was useful for discriminating cancer (area under the ROC curve, 0.864) or IPMN (area under the ROC curve, 0.749) from chronic pancreatitis. The present data suggest that expression of S100A6 is increased in a stepwise manner during pancreatic carcinogenesis and may be a biomarker for evaluating malignant potential. Measurement of S100A6 in pancreatic juice may be useful to detect early pancreatic cancer or identify individuals with high-risk lesions that may progress to pancreatic cancer.",
author = "Kenoki Ohuchida and Kazuhiro Mizumoto and Jun Yu and Hiroshi Yamaguchi and Hiroyuki Konomi and Eishi Nagai and Koji Yamaguchi and Masazumi Tsuneyoshi and Masao Tanaka",
year = "2007",
month = "4",
doi = "10.1158/1055-9965.EPI-06-0157",
language = "English (US)",
volume = "16",
pages = "649--654",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - S100A6 is increased in a stepwise manner during pancreatic carcinogenesis

T2 - Clinical value of expression analysis in 98 pancreatic juice samples

AU - Ohuchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Yu, Jun

AU - Yamaguchi, Hiroshi

AU - Konomi, Hiroyuki

AU - Nagai, Eishi

AU - Yamaguchi, Koji

AU - Tsuneyoshi, Masazumi

AU - Tanaka, Masao

PY - 2007/4

Y1 - 2007/4

N2 - There are few reports describing the diagnostic significance of S100A6 expression in clinical samples obtained from patients with pancreatic disease. In the present study, we measured S100A6 expression in pancreatic tissues and juice to evaluate its involvement in pancreatic carcinogenesis. We did quantitative real-time reverse transcription-PCR to measure mRNA expression in microdissected cells and pancreatic juice samples. Microdissected invasive ductal carcinoma and intraductal papillary mucinous neoplasm (IPMN) cells expressed significantly higher levels of S100A6 than did microdissected pancreatitis-affected epithelial and normal cells (all comparison; P <0.008). Median levels of S100A6 in invasive ductal carcinoma were higher than those in IPMN, and those in pancreatitis-affected epithelial cells tended to be higher than those in normal cells, although these differences were not statistically significant. In analyses of pancreatic juice, IPMN and pancreatic cancer samples expressed significantly higher levels of S100A6 than did chronic pancreatitis samples (both; P <0.017), but levels in pancreatic cancer and IPMN samples did not differ form each other. Receiver operating characteristic (ROC) curve analysis revealed that measurement of S100A6 was useful for discriminating cancer (area under the ROC curve, 0.864) or IPMN (area under the ROC curve, 0.749) from chronic pancreatitis. The present data suggest that expression of S100A6 is increased in a stepwise manner during pancreatic carcinogenesis and may be a biomarker for evaluating malignant potential. Measurement of S100A6 in pancreatic juice may be useful to detect early pancreatic cancer or identify individuals with high-risk lesions that may progress to pancreatic cancer.

AB - There are few reports describing the diagnostic significance of S100A6 expression in clinical samples obtained from patients with pancreatic disease. In the present study, we measured S100A6 expression in pancreatic tissues and juice to evaluate its involvement in pancreatic carcinogenesis. We did quantitative real-time reverse transcription-PCR to measure mRNA expression in microdissected cells and pancreatic juice samples. Microdissected invasive ductal carcinoma and intraductal papillary mucinous neoplasm (IPMN) cells expressed significantly higher levels of S100A6 than did microdissected pancreatitis-affected epithelial and normal cells (all comparison; P <0.008). Median levels of S100A6 in invasive ductal carcinoma were higher than those in IPMN, and those in pancreatitis-affected epithelial cells tended to be higher than those in normal cells, although these differences were not statistically significant. In analyses of pancreatic juice, IPMN and pancreatic cancer samples expressed significantly higher levels of S100A6 than did chronic pancreatitis samples (both; P <0.017), but levels in pancreatic cancer and IPMN samples did not differ form each other. Receiver operating characteristic (ROC) curve analysis revealed that measurement of S100A6 was useful for discriminating cancer (area under the ROC curve, 0.864) or IPMN (area under the ROC curve, 0.749) from chronic pancreatitis. The present data suggest that expression of S100A6 is increased in a stepwise manner during pancreatic carcinogenesis and may be a biomarker for evaluating malignant potential. Measurement of S100A6 in pancreatic juice may be useful to detect early pancreatic cancer or identify individuals with high-risk lesions that may progress to pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=34247489263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247489263&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0157

DO - 10.1158/1055-9965.EPI-06-0157

M3 - Article

C2 - 17416753

AN - SCOPUS:34247489263

VL - 16

SP - 649

EP - 654

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -